Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 125 citing articles:

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 493
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, et al.
Hepatology (2020) Vol. 73, Iss. S1, pp. 158-191
Open Access | Times Cited: 322
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo, Kwang–Hyub Han, Sheng-Long Ye, et al.
Liver Cancer (2020) Vol. 9, Iss. 3, pp. 245-260
Open Access | Times Cited: 240
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Jiayi Wu, Zhenyu Yin, Yannan Bai, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1233-1240
Open Access | Times Cited: 105
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 354-367
Open Access | Times Cited: 90
Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 81
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 68
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 45
Cisplatin in Liver Cancer Therapy
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 43
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update
Masatoshi Kudo
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 640-662
Open Access | Times Cited: 94
Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma
Mingyu Chen, Jiasheng Cao, Jiahao Hu, et al.
Liver Cancer (2021) Vol. 10, Iss. 1, pp. 38-51
Open Access | Times Cited: 89
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Masatoshi Kudo
Liver Cancer (2021) Vol. 10, Iss. 6, pp. 539-544
Open Access | Times Cited: 69
The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Fei Cao, Yi Yang, Tongguo Si, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 68
Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?
Ti Zhang, Philippe Merle, Huaqi Wang, et al.
HepatoBiliary Surgery and Nutrition (2021) Vol. 10, Iss. 2, pp. 180-192
Open Access | Times Cited: 60
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2022) Vol. 11, Iss. 5, pp. 399-406
Open Access | Times Cited: 55
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Takeshi Hatanaka, Yutaka Yata, Atsushi Naganuma, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1798-1798
Open Access | Times Cited: 28
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 25
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 756-770
Open Access | Times Cited: 59
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Liver Cancer (2020) Vol. 9, Iss. 2, pp. 119-137
Open Access | Times Cited: 56
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
Yuwa Ando, Tomokazu Kawaoka, Kei Amioka, et al.
Oncology (2021) Vol. 99, Iss. 8, pp. 507-517
Closed Access | Times Cited: 50
Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria
Ya-Wen Hung, I-Cheng Lee, Chen-Ta Chi, et al.
Liver Cancer (2021) Vol. 10, Iss. 6, pp. 629-640
Open Access | Times Cited: 44
Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Evgenia Kotsifa, Chrysovalantis Vergadis, Michail Vailas, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 436-436
Open Access | Times Cited: 36
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Masatoshi Kudo
International Journal of Clinical Oncology (2022) Vol. 27, Iss. 7, pp. 1110-1119
Open Access | Times Cited: 32
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Jiayi Wu, Zhibo Zhang, Jianyin Zhou, et al.
Liver Cancer (2022) Vol. 12, Iss. 3, pp. 229-237
Open Access | Times Cited: 31
Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
Bo Sun, Lijie Zhang, Tao Sun, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top